The weight loss medication tirzepatide (Mounjaro and Zepbound) is no longer in shortage, according to the FDA. Access to ...
The U.S. Food and Drug Administration reissued a decision first made by the agency in October that a shortage of the diabetes ...
The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide ...
On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a Declaratory Order reevaluating and re-confirming that the tirzepatide ...
Tirzepatide, the active ingredient in both Mounjaro for type 2 diabetes and Zepbound for weight loss, was in short supply for ...
Hims & Hers Health (NYSE:HIMS) is down 7% in early morning trading after the U.S. FDA determined that there is no shortage of ...
Hims & Hers faces regulatory hurdles but shows strong business growth. Find out why HIMS stock is a "Hold" despite setbacks ...
Approved in 2022 for type 2 diabetes and in 2023 for chronic weight management along with diet and exercise, tirzepatide is ...
Leerink notes that the FDA today declared an end to the tirzepatide shortage, which “seemingly begins the process of bringing the compounded ...
Nestle just rolled out a new protein shot drink that it says will help people looking to lose weight manage their hunger and ...
Credit: Eli Lilly. Tirzepatide includes blockbuster injected GLP-1 medications Mounjaro (for diabetes) and Zepbound (for weight loss). Compounding pharmacies must now cease producing the lucrative ...